EUVIMEDEUVIMED entdecken
Crossref

Utility of Inhaled Nitric Oxide Vasoreactivity Challenge in Pulmonary Hypertension Associated with Interstitial Lung Disease

Mamta S Chhabria, Gaurav Manek, Purnadeo N Persaud, Sravanthi Ennala, Bathmapriya Balakrishnan, Samar Farha, Adriano R Tonelli

Annals of the American Thoracic Society · 2025

DOI: 10.1513/annalsats.202502-148oc ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the American Thoracic Society, 2025. Verfasst von Mamta S Chhabria und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Mayo Clinic Health System, Eau Claire, WI, United States. Hauptthemen laut MEDLINE: Nitric Oxide, Hypertension, Pulmonary, Lung Diseases, Interstitial.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with pulmonary hypertension due to interstitial lung disease (PH-ILD) have worse exercise capacity and survival than ILD patients without PH. Vasoreactivity with inhaled nitric oxide (NO) provides prognostic and therapeutic implications in pulmonary arterial hypertension, but little is known on its value in PH-ILD. We evaluated the pulmonary hemodynamic changes following inhaled NO and their association with outcomes in PH-ILD.

Methods

We measured pulmonary hemodynamics in patients with PH-ILD who underwent inhaled NO administration during right heart catheterization. We recorded baseline clinical, echocardiographic, and pulmonary function testing measures; and investigated the use of inhaled treprostinil as well as the rate of hospitalization, death and lung transplantation.

Results

In 120 patients (age 67 ± 11 years, 62% women), the administration of inhaled NO resulted in a median (IQR) decrease in mean pulmonary artery pressure (mPAP) of -3 (-5, -1) mmHg, p<0.001, and PVR of -0.8 (-1.8, -0.2) Wood units, p<0.001. The % change in mPAP and PVR were -6.3 (-10.9, -1.8) % and -16.8 (-27.3, -3.3) %, respectively. Factors associated with the % drop in PVR included baseline PVR (r= 0.30, p<0.001), cardiac output (r= -0.19, p=0.04), and WHO functional class (r=0.25, p=0.01). The median (IQR) follow-up was 14.5 (7, 25) months. During this time, 40 (33%) patients died, 8 (7%) underwent lung transplantation, and 76 (63%) experienced either hospitalization due to respiratory failure, transplantation, or death. The % drop in mPAP and PVR during inhalation of NO had no significant impact on these outcomes and was not associated with clinical response to inhaled treprostinil measured by changes in six-minute walk distance (6MWD) and forced vital capacity (FVC).

Conclusion

Inhaled NO caused a modest reduction in mPAP and PVR in patients with PH-ILD, but the acute hemodynamic response to inhaled NO, in our cohort, was not associated with outcomes or response to inhaled treprostinil therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nitric OxideHypertension, PulmonaryLung Diseases, InterstitialHumansFemaleMaleAgedAdministration, InhalationMiddle AgedVascular ResistanceEpoprostenolCardiac CatheterizationLung TransplantationAntihypertensive AgentsHemodynamicsVasodilator Agents

Stichwörter der Autor:innen

inhaled nitric oxideinterstitial lung diseasepulmonary hypertensionpulmonary vasoreactivitysurvival

Substanzen

Nitric OxideEpoprostenolAntihypertensive AgentstreprostinilVasodilator Agents

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Mayo Clinic Health System, Eau Claire, WI, United States.
  • Department of Pulmonary and Critical Care Medicine, MedStar Health, Clinton, MD, United States.
  • Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, United States.

Zitieren

APA

Chhabria, M. S., Manek, G., Persaud, P. N., Ennala, S., Balakrishnan, B., Farha, S., & Tonelli, A. R. (2025). Utility of Inhaled Nitric Oxide Vasoreactivity Challenge in Pulmonary Hypertension Associated with Interstitial Lung Disease. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.202502-148oc

Vancouver

Chhabria MS, Manek G, Persaud PN, Ennala S, Balakrishnan B, Farha S, et al. Utility of Inhaled Nitric Oxide Vasoreactivity Challenge in Pulmonary Hypertension Associated with Interstitial Lung Disease. Annals of the American Thoracic Society. 2025. doi:10.1513/annalsats.202502-148oc

BibTeX
@article{Chhabria2025,
  author = {Chhabria, Mamta S and Manek, Gaurav and Persaud, Purnadeo N and Ennala, Sravanthi and Balakrishnan, Bathmapriya and Farha, Samar and Tonelli, Adriano R},
  title = {Utility of Inhaled Nitric Oxide Vasoreactivity Challenge in Pulmonary Hypertension Associated with Interstitial Lung Disease},
  journal = {Annals of the American Thoracic Society},
  year = {2025},
  doi = {10.1513/annalsats.202502-148oc}
}
Kostenlos starten →